Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2023 Results
- Thermo Fisher reported a 5% increase in Q4 GAAP diluted EPS and a 5% increase in adjusted EPS compared to the same quarter last year.
- The company executed its capital deployment strategy, completed the acquisitions of The Binding Site and CorEvitas, and announced an agreement to acquire Olink Holding AB (publ).
- Thermo Fisher initiated a guidance range for full year 2024 with revenue of $42.1 billion to $43.3 billion and adjusted EPS of $20.95 to $22.00.
- The company reported a 5% decrease in Q4 revenue compared to the same quarter last year.
- Full-year revenue was 5% lower than the previous year.
Insights
The reported decrease in Thermo Fisher Scientific's fourth quarter revenue by 5% year-over-year, alongside a 4% decline in core organic revenue growth, indicates a contraction in the company's business operations relative to the same period last year. However, this needs to be juxtaposed with the increase in both GAAP diluted EPS and adjusted EPS by 5%, suggesting effective cost management and possibly a favorable product mix or pricing power that has allowed for margin expansion despite top-line pressures.
From a financial perspective, the operating margin improvements, both GAAP and adjusted, are noteworthy. A 70 basis points increase in GAAP operating margin and a 100 basis points increase in adjusted operating margin reflect operational efficiency gains, potentially derived from the company's PPI Business System. This operational excellence could be a key driver in maintaining profitability in a potentially challenging revenue environment.
The capital return to shareholders through stock buybacks and dividends, amounting to $3.5 billion, underscores a shareholder-friendly capital allocation policy. However, the forward guidance for 2024 with a projected revenue range of $42.1 billion to $43.3 billion and adjusted EPS of $20.95 to $22.00 suggests a cautious outlook, which might be factoring in the ongoing macroeconomic uncertainties and the normalization of COVID-19 testing revenue.
Thermo Fisher's product launches, such as the Orbitrap™ Astral™ mass spectrometer and the Aquanex™ Ultrapure Water Purification System, signal ongoing innovation and expansion of the company's product portfolio. This is crucial for maintaining competitive advantage and customer engagement in the life sciences and analytical instruments industry. The strategic acquisitions of The Binding Site and CorEvitas, along with the agreement to acquire Olink, indicate a deliberate expansion into high-growth areas such as diagnostics and real-world evidence generation.
The opening of a customer experience center for battery manufacturing in Seoul demonstrates Thermo Fisher's commitment to aligning with global industry trends, such as the shift towards environmentally friendly energy solutions. This move might cater to the growing demand in the materials science sector, which is pivotal for the development of next-generation batteries.
Thermo Fisher's emphasis on corporate social responsibility (CSR), including initiatives for global health equity and STEM education, may enhance its brand reputation and strengthen customer relationships. Such initiatives can also foster long-term loyalty and potentially create new market opportunities in underserved regions.
The accelerated progress towards utilizing 80% renewable electricity globally by 2030, as part of Thermo Fisher's net-zero roadmap, aligns with broader sustainability trends and investor expectations regarding environmental stewardship. This could positively influence investor sentiment, particularly among ESG-focused funds and potentially mitigate regulatory risks associated with carbon emissions.
Thermo Fisher's efforts in expanding access to advanced genomic testing in low- and middle-income countries and bringing clinical trials to historically underserved patient populations reflect a commitment to social aspects of ESG. This not only addresses global health disparities but may also open up new markets and drive innovation by incorporating diverse patient data into research and development processes.
Fourth Quarter and Full Year 2023 Highlights
-
Fourth quarter revenue was
$10.89 billion 5% lower versus the same quarter last year. Core organic revenue growth declined4% . -
Fourth quarter GAAP diluted EPS was
$4.20 5% higher versus the same quarter last year, driven by 70 basis points of operating margin expansion. -
Fourth quarter adjusted EPS was
$5.67 5% higher versus the same quarter last year, driven by 100 basis points of adjusted operating margin expansion.
-
Full year revenue was
$42.86 billion 5% lower versus prior year. Core organic revenue growth was1% . -
Full year GAAP diluted earnings per share (EPS) was
$15.45 -
Full year adjusted EPS was
$21.55
- During the year, we strengthened our industry leadership, advanced our trusted partner status with our customers, and delivered differentiated financial performance for our shareholders due to strong execution by our global team enabled by our PPI Business System.
- Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the year, highlighted by the groundbreaking Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, the Applied Biosystems™ QuantStudio™ Absolute Q™ AutoRun dPCR System, the Thermo Scientific™ Metrios™ 6 S/TEM, the first FDA-cleared assays for risk assessment and clinical management of preeclampsia, and the Gibco™ CTS™ Detachable Dynabeads™. During the quarter, we launched the Thermo Scientific™ Meridian™ EX System, an electron-beam-based solution for precise defect localization in advanced logic semiconductors and the Thermo Scientific™ Aquanex™ Ultrapure Water Purification System, for reliable water purity and operational enhancement in laboratories.
-
Continued to further strengthen our industry-leading commercial engine and deepen our trusted partner status during the year, as demonstrated by our differentiated performance in 2023. This included the addition of a new customer excellence center in
Europe , partnering and collaborating with customers on innovative new medicines, and leveraging digital tools to further optimize commercial effectiveness and improve the customer experience. During the fourth quarter, we opened a customer experience center for battery manufacturing inSeoul to support our material science customers as they accelerate the development of the next generation of environmentally friendly energy solutions.
-
Strong year advancing our corporate social responsibility (CSR) priorities. We accelerated our net-zero roadmap with on-site solar projects and power purchase agreements across the
Americas ,Europe andAsia Pacific regions, advancing our progress toward our target of utilizing80% renewable electricity globally by 2030. We also progressed our global health equity initiatives by offering expanded access to advanced genomic testing in low- and middle-income countries and launched new initiatives to continue bringing clinical trials to historically underserved patient populations. We further engaged in supporting local communities through our colleague-led STEM education programs.
-
Continued to successfully execute our capital deployment strategy in 2023. During the year we completed the acquisitions of The Binding Site, a leading provider for detection and monitoring of multiple myeloma, and CorEvitas, a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. We also announced an agreement to acquire Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading solution for advanced proteomics discovery and development. Additionally, we returned
$3.5 billion
“Thanks to the strong contributions from our team, we delivered differentiated performance in 2023 and enabled our customers’ success,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “We effectively navigated the challenging macroeconomic conditions by leveraging our PPI Business System to deliver strong financial results.”
Casper added, “Our proven growth strategy, capital deployment approach, and PPI Business System, continue to position our company for an even brighter future.”
Fourth Quarter 2023
Revenue for the quarter declined
GAAP Earnings Results
GAAP diluted EPS in the fourth quarter of 2023 was
Non-GAAP Earnings Results
Adjusted EPS in the fourth quarter of 2023 was
Full Year 2023
Revenue for the full year declined
GAAP Earnings Results
GAAP diluted EPS for the full year was
Non-GAAP Earnings Results
Adjusted EPS for the full year was
Annual Guidance for 2024
Thermo Fisher is initiating a guidance range for full year 2024 with revenue of
Use of Non-GAAP Financial Measures
Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, organic revenue growth and Core organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading “Supplemental Information Regarding Non-GAAP Financial Measures.” The reconciliations of GAAP to non-GAAP financial measures are provided in the tables that accompany this press release.
Conference Call
During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over
Safe Harbor Statement
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, including our pending acquisition of Olink, may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
Additional Information and Where to Find It
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any common shares or American Depositary Shares of Olink or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or Orion Acquisition AB (the “Buyer”) has filed with the SEC. The terms and conditions of the tender offer are published in, and the offer to purchase common shares and American Depositary Shares of Olink is made only pursuant to, the offer document and related offer materials prepared by Thermo Fisher and the Buyer and is filed with the SEC in a tender offer statement on Schedule TO. In addition, Olink has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer.
THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, AN ADS LETTER OF TRANSMITTAL, ACCEPTANCE FORM FOR SHARES AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION. INVESTORS AND SHAREHOLDERS OF OLINK ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY, AND NOT THIS DOCUMENT, GOVERN THE TERMS AND CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON SHARES AND AMERICAN DEPOSITARY SHARES.
The tender offer materials, including the offer to purchase, the related ADS letter of transmittal and acceptance form for shares and certain other tender offer documents, and the solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or Olink, may be obtained free of charge at the SEC's website at www.sec.gov, at Olink’s website https://investors.olink.com/investor-relations, at Thermo Fisher's website at www.thermofisher.com or by contacting Thermo Fisher's investor relations department at 781-622-1111.
Condensed Consolidated Statements of Income (unaudited) |
|
|
|
|
|
|
|
|
||||||
|
|
Three months ended |
||||||||||||
|
|
December 31, |
|
% of |
|
December 31, |
|
% of |
||||||
(Dollars in millions except per share amounts) |
|
|
2023 |
|
|
Revenues |
|
|
2022 |
|
|
Revenues |
||
Revenues |
|
$ |
10,886 |
|
|
|
|
$ |
11,450 |
|
|
|
||
Costs and operating expenses: |
|
|
|
|
|
|
|
|
||||||
Cost of revenues (a) |
|
|
6,390 |
|
|
58.7 |
% |
|
|
6,715 |
|
|
58.6 |
% |
Selling, general and administrative expenses (b) |
|
|
1,672 |
|
|
15.4 |
% |
|
|
1,836 |
|
|
16.0 |
% |
Amortization of acquisition-related intangible assets |
|
|
563 |
|
|
5.2 |
% |
|
|
592 |
|
|
5.2 |
% |
Research and development expenses |
|
|
327 |
|
|
3.0 |
% |
|
|
391 |
|
|
3.4 |
% |
Restructuring and other costs (c) |
|
|
80 |
|
|
0.7 |
% |
|
|
55 |
|
|
0.5 |
% |
Total costs and operating expenses |
|
|
9,032 |
|
|
83.0 |
% |
|
|
9,589 |
|
|
83.7 |
% |
Operating income |
|
|
1,854 |
|
|
17.0 |
% |
|
|
1,861 |
|
|
16.3 |
% |
Interest income |
|
|
309 |
|
|
|
|
|
150 |
|
|
|
||
Interest expense |
|
|
(390 |
) |
|
|
|
|
(269 |
) |
|
|
||
Other income/(expense) (d) |
|
|
(33 |
) |
|
|
|
|
35 |
|
|
|
||
Income before income taxes |
|
|
1,740 |
|
|
|
|
|
1,777 |
|
|
|
||
Provision for income taxes (e) |
|
|
(133 |
) |
|
|
|
|
(173 |
) |
|
|
||
Equity in earnings/(losses) of unconsolidated entities |
|
|
(1 |
) |
|
|
|
|
(30 |
) |
|
|
||
Net income |
|
|
1,606 |
|
|
|
|
|
1,574 |
|
|
|
||
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest |
|
|
(24 |
) |
|
|
|
|
(2 |
) |
|
|
||
Net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
1,630 |
|
|
15.0 |
% |
|
$ |
1,576 |
|
|
13.8 |
% |
|
|
|
|
|
|
|
|
|
||||||
Earnings per share attributable to Thermo Fisher Scientific Inc.: |
|
|
|
|
|
|
|
|
||||||
Basic |
|
$ |
4.22 |
|
|
|
|
$ |
4.03 |
|
|
|
||
Diluted |
|
$ |
4.20 |
|
|
|
|
$ |
4.01 |
|
|
|
||
Weighted average shares: |
|
|
|
|
|
|
|
|
||||||
Basic |
|
|
387 |
|
|
|
|
|
391 |
|
|
|
||
Diluted |
|
|
388 |
|
|
|
|
|
393 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted operating income and adjusted operating margin |
|
|
|
|
|
|
|
|
||||||
GAAP operating income |
|
$ |
1,854 |
|
|
17.0 |
% |
|
$ |
1,861 |
|
|
16.3 |
% |
Cost of revenues adjustments (a) |
|
|
22 |
|
|
0.2 |
% |
|
|
5 |
|
|
0.0 |
% |
Selling, general and administrative expenses adjustments (b) |
|
|
31 |
|
|
0.3 |
% |
|
|
47 |
|
|
0.4 |
% |
Restructuring and other costs (c) |
|
|
80 |
|
|
0.7 |
% |
|
|
55 |
|
|
0.5 |
% |
Amortization of acquisition-related intangible assets |
|
|
563 |
|
|
5.2 |
% |
|
|
592 |
|
|
5.2 |
% |
Adjusted operating income (non-GAAP measure) |
|
$ |
2,550 |
|
|
23.4 |
% |
|
$ |
2,560 |
|
|
22.4 |
% |
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted net income |
|
|
|
|
|
|
|
|
||||||
GAAP net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
1,630 |
|
|
|
|
$ |
1,576 |
|
|
|
||
Cost of revenues adjustments (a) |
|
|
22 |
|
|
|
|
|
5 |
|
|
|
||
Selling, general and administrative expenses adjustments (b) |
|
|
31 |
|
|
|
|
|
47 |
|
|
|
||
Restructuring and other costs (c) |
|
|
80 |
|
|
|
|
|
55 |
|
|
|
||
Amortization of acquisition-related intangible assets |
|
|
563 |
|
|
|
|
|
592 |
|
|
|
||
Other income/expense adjustments (d) |
|
|
14 |
|
|
|
|
|
(46 |
) |
|
|
||
Provision for income taxes adjustments (e) |
|
|
(111 |
) |
|
|
|
|
(138 |
) |
|
|
||
Equity in earnings/losses of unconsolidated entities |
|
|
1 |
|
|
|
|
|
30 |
|
|
|
||
Noncontrolling interests adjustments (f) |
|
|
(27 |
) |
|
|
|
|
— |
|
|
|
||
Adjusted net income (non-GAAP measure) |
|
$ |
2,203 |
|
|
|
|
$ |
2,121 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted earnings per share |
|
|
|
|
|
|
|
|
||||||
GAAP diluted EPS attributable to Thermo Fisher Scientific Inc. |
|
$ |
4.20 |
|
|
|
|
$ |
4.01 |
|
|
|
||
Cost of revenues adjustments (a) |
|
|
0.06 |
|
|
|
|
|
0.01 |
|
|
|
||
Selling, general and administrative expenses adjustments (b) |
|
|
0.08 |
|
|
|
|
|
0.12 |
|
|
|
||
Restructuring and other costs (c) |
|
|
0.20 |
|
|
|
|
|
0.14 |
|
|
|
||
Amortization of acquisition-related intangible assets |
|
|
1.45 |
|
|
|
|
|
1.50 |
|
|
|
||
Other income/expense adjustments (d) |
|
|
0.04 |
|
|
|
|
|
(0.11 |
) |
|
|
||
Provision for income taxes adjustments (e) |
|
|
(0.29 |
) |
|
|
|
|
(0.35 |
) |
|
|
||
Equity in earnings/losses of unconsolidated entities |
|
|
0.00 |
|
|
|
|
|
0.08 |
|
|
|
||
Noncontrolling interests adjustments (f) |
|
|
(0.07 |
) |
|
|
|
|
0.00 |
|
|
|
||
Adjusted EPS (non-GAAP measure) |
|
$ |
5.67 |
|
|
|
|
$ |
5.40 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of free cash flow |
|
|
|
|
|
|
|
|
||||||
GAAP net cash provided by operating activities |
|
$ |
3,723 |
|
|
|
|
$ |
3,487 |
|
|
|
||
Purchases of property, plant and equipment |
|
|
(405 |
) |
|
|
|
|
(550 |
) |
|
|
||
Proceeds from sale of property, plant and equipment |
|
|
11 |
|
|
|
|
|
6 |
|
|
|
||
Free cash flow (non-GAAP measure) |
|
$ |
3,329 |
|
|
|
|
$ |
2,943 |
|
|
|
||
Business Segment Information |
|
Three months ended |
||||||||||||
|
|
December 31, |
|
% of |
|
December 31, |
|
% of |
||||||
(Dollars in millions) |
|
|
2023 |
|
|
Revenues |
|
|
2022 |
|
|
Revenues |
||
|
|
|
|
|
|
|
|
|
||||||
Revenues |
|
|
|
|
|
|
|
|
||||||
Life Sciences Solutions |
|
$ |
2,469 |
|
|
22.7 |
% |
|
$ |
3,046 |
|
|
26.6 |
% |
Analytical Instruments |
|
|
2,037 |
|
|
18.7 |
% |
|
|
1,878 |
|
|
16.4 |
% |
Specialty Diagnostics |
|
|
1,105 |
|
|
10.2 |
% |
|
|
1,115 |
|
|
9.7 |
% |
Laboratory Products and Biopharma Services |
|
|
5,719 |
|
|
52.5 |
% |
|
|
5,947 |
|
|
51.9 |
% |
Eliminations |
|
|
(444 |
) |
|
-4.1 |
% |
|
|
(536 |
) |
|
-4.6 |
% |
Consolidated revenues |
|
$ |
10,886 |
|
|
100.0 |
% |
|
$ |
11,450 |
|
|
100.0 |
% |
|
|
|
|
|
|
|
|
|
||||||
Segment income and segment income margin |
|
|
|
|
|
|
|
|
||||||
Life Sciences Solutions |
|
$ |
895 |
|
|
36.2 |
% |
|
$ |
1,040 |
|
|
34.1 |
% |
Analytical Instruments |
|
|
587 |
|
|
28.8 |
% |
|
|
476 |
|
|
25.4 |
% |
Specialty Diagnostics |
|
|
264 |
|
|
23.9 |
% |
|
|
208 |
|
|
18.6 |
% |
Laboratory Products and Biopharma Services |
|
|
804 |
|
|
14.0 |
% |
|
|
836 |
|
|
14.1 |
% |
Subtotal reportable segments |
|
|
2,550 |
|
|
23.4 |
% |
|
|
2,560 |
|
|
22.4 |
% |
Cost of revenues adjustments (a) |
|
|
(22 |
) |
|
-0.2 |
% |
|
|
(5 |
) |
|
0.0 |
% |
Selling, general and administrative expenses adjustments (b) |
|
|
(31 |
) |
|
-0.3 |
% |
|
|
(47 |
) |
|
-0.4 |
% |
Restructuring and other costs (c) |
|
|
(80 |
) |
|
-0.7 |
% |
|
|
(55 |
) |
|
-0.5 |
% |
Amortization of acquisition-related intangible assets |
|
|
(563 |
) |
|
-5.2 |
% |
|
|
(592 |
) |
|
-5.2 |
% |
Consolidated GAAP operating income |
|
$ |
1,854 |
|
|
17.0 |
% |
|
$ |
1,861 |
|
|
16.3 |
% |
(a) Adjusted results in 2023 exclude |
(b) Adjusted results in 2023 and 2022 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges associated with product liability litigation. |
(c) Adjusted results in 2023 and 2022 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, charges for environmental-related matters, abandoned facility, and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude |
(d) Adjusted results in 2023 and 2022 exclude net gains/losses on investments. Adjusted results in 2022 also exclude |
(e) Adjusted results in 2023 and 2022 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes, and the tax impacts from audit settlements. Adjusted results in 2023 also exclude |
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests. |
Note: |
Consolidated depreciation expense is |
Organic and Core organic revenue growth |
|
Three months ended |
|
|
December 31, 2023 |
Revenue growth |
|
- |
Acquisitions |
|
|
Currency translation |
|
|
Organic revenue growth (non-GAAP measure) * |
|
- |
COVID-19 testing revenue |
|
- |
Core organic revenue growth (non-GAAP measure) * |
|
- |
* Results may not sum due to rounding. |
|
|
Note: |
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
Condensed Consolidated Statements of Income (unaudited) |
|
|
|
|
|
|
|
|
||||||
|
|
Year ended |
||||||||||||
|
|
December 31, |
|
% of |
|
December 31, |
|
% of |
||||||
(Dollars in millions except per share amounts) |
|
|
2023 |
|
|
Revenues |
|
|
2022 |
|
|
Revenues |
||
Revenues |
|
$ |
42,857 |
|
|
|
|
$ |
44,915 |
|
|
|
||
Costs and operating expenses: |
|
|
|
|
|
|
|
|
||||||
Cost of revenues (a) |
|
|
25,295 |
|
|
59.0 |
% |
|
|
25,415 |
|
|
56.6 |
% |
Selling, general and administrative expenses (b) |
|
|
6,569 |
|
|
15.3 |
% |
|
|
7,127 |
|
|
15.9 |
% |
Amortization of acquisition-related intangible assets |
|
|
2,338 |
|
|
5.5 |
% |
|
|
2,395 |
|
|
5.3 |
% |
Research and development expenses |
|
|
1,337 |
|
|
3.1 |
% |
|
|
1,471 |
|
|
3.3 |
% |
Restructuring and other costs (c) |
|
|
459 |
|
|
1.1 |
% |
|
|
114 |
|
|
0.3 |
% |
Total costs and operating expenses |
|
|
35,998 |
|
|
84.0 |
% |
|
|
36,522 |
|
|
81.3 |
% |
Operating income |
|
|
6,859 |
|
|
16.0 |
% |
|
|
8,393 |
|
|
18.7 |
% |
Interest income |
|
|
879 |
|
|
|
|
|
272 |
|
|
|
||
Interest expense |
|
|
(1,375 |
) |
|
|
|
|
(726 |
) |
|
|
||
Other income/(expense) (d) |
|
|
(65 |
) |
|
|
|
|
(104 |
) |
|
|
||
Income before income taxes |
|
|
6,298 |
|
|
|
|
|
7,835 |
|
|
|
||
Provision for income taxes (e) |
|
|
(284 |
) |
|
|
|
|
(703 |
) |
|
|
||
Equity in earnings/(losses) of unconsolidated entities |
|
|
(59 |
) |
|
|
|
|
(172 |
) |
|
|
||
Net income |
|
|
5,955 |
|
|
|
|
|
6,960 |
|
|
|
||
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest |
|
|
(40 |
) |
|
|
|
|
10 |
|
|
|
||
Net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
5,995 |
|
|
14.0 |
% |
|
$ |
6,950 |
|
|
15.5 |
% |
|
|
|
|
|
|
|
|
|
||||||
Earnings per share attributable to Thermo Fisher Scientific Inc.: |
|
|
|
|
|
|
|
|
||||||
Basic |
|
$ |
15.52 |
|
|
|
|
$ |
17.75 |
|
|
|
||
Diluted |
|
$ |
15.45 |
|
|
|
|
$ |
17.63 |
|
|
|
||
Weighted average shares: |
|
|
|
|
|
|
|
|
||||||
Basic |
|
|
386 |
|
|
|
|
|
392 |
|
|
|
||
Diluted |
|
|
388 |
|
|
|
|
|
394 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted operating income and adjusted operating margin |
|
|
|
|
|
|
|
|
||||||
GAAP operating income |
|
$ |
6,859 |
|
|
16.0 |
% |
|
$ |
8,393 |
|
|
18.7 |
% |
Cost of revenues adjustments (a) |
|
|
95 |
|
|
0.2 |
% |
|
|
46 |
|
|
0.1 |
% |
Selling, general and administrative expenses adjustments (b) |
|
|
59 |
|
|
0.1 |
% |
|
|
37 |
|
|
0.1 |
% |
Restructuring and other costs (c) |
|
|
459 |
|
|
1.1 |
% |
|
|
114 |
|
|
0.3 |
% |
Amortization of acquisition-related intangible assets |
|
|
2,338 |
|
|
5.5 |
% |
|
|
2,395 |
|
|
5.3 |
% |
Adjusted operating income (non-GAAP measure) |
|
$ |
9,810 |
|
|
22.9 |
% |
|
$ |
10,985 |
|
|
24.5 |
% |
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted net income |
|
|
|
|
|
|
|
|
||||||
GAAP net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
5,995 |
|
|
|
|
$ |
6,950 |
|
|
|
||
Cost of revenues adjustments (a) |
|
|
95 |
|
|
|
|
|
46 |
|
|
|
||
Selling, general and administrative expenses adjustments (b) |
|
|
59 |
|
|
|
|
|
37 |
|
|
|
||
Restructuring and other costs (c) |
|
|
459 |
|
|
|
|
|
114 |
|
|
|
||
Amortization of acquisition-related intangible assets |
|
|
2,338 |
|
|
|
|
|
2,395 |
|
|
|
||
Other income/expense adjustments (d) |
|
|
50 |
|
|
|
|
|
117 |
|
|
|
||
Provision for income taxes adjustments (e) |
|
|
(645 |
) |
|
|
|
|
(672 |
) |
|
|
||
Equity in earnings/losses of unconsolidated entities |
|
|
59 |
|
|
|
|
|
172 |
|
|
|
||
Noncontrolling interests adjustments (f) |
|
|
(46 |
) |
|
|
|
|
— |
|
|
|
||
Adjusted net income (non-GAAP measure) |
|
$ |
8,364 |
|
|
|
|
$ |
9,159 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted earnings per share |
|
|
|
|
|
|
|
|
||||||
GAAP diluted EPS attributable to Thermo Fisher Scientific Inc. |
|
$ |
15.45 |
|
|
|
|
$ |
17.63 |
|
|
|
||
Cost of revenues adjustments (a) |
|
|
0.24 |
|
|
|
|
|
0.12 |
|
|
|
||
Selling, general and administrative expenses adjustments (b) |
|
|
0.15 |
|
|
|
|
|
0.09 |
|
|
|
||
Restructuring and other costs (c) |
|
|
1.18 |
|
|
|
|
|
0.29 |
|
|
|
||
Amortization of acquisition-related intangible assets |
|
|
6.03 |
|
|
|
|
|
6.07 |
|
|
|
||
Other income/expense adjustments (d) |
|
|
0.13 |
|
|
|
|
|
0.30 |
|
|
|
||
Provision for income taxes adjustments (e) |
|
|
(1.66 |
) |
|
|
|
|
(1.70 |
) |
|
|
||
Equity in earnings/losses of unconsolidated entities |
|
|
0.15 |
|
|
|
|
|
0.44 |
|
|
|
||
Noncontrolling interests adjustments (f) |
|
|
(0.12 |
) |
|
|
|
|
0.00 |
|
|
|
||
Adjusted EPS (non-GAAP measure) |
|
$ |
21.55 |
|
|
|
|
$ |
23.24 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of free cash flow |
|
|
|
|
|
|
|
|
||||||
GAAP net cash provided by operating activities |
|
$ |
8,406 |
|
|
|
|
$ |
9,154 |
|
|
|
||
Purchases of property, plant and equipment |
|
|
(1,479 |
) |
|
|
|
|
(2,243 |
) |
|
|
||
Proceeds from sale of property, plant and equipment |
|
|
87 |
|
|
|
|
|
24 |
|
|
|
||
Free cash flow (non-GAAP measure) |
|
$ |
7,014 |
|
|
|
|
$ |
6,935 |
|
|
|
||
Business Segment Information |
|
Year ended |
||||||||||||
|
|
December 31, |
|
% of |
|
December 31, |
|
% of |
||||||
(Dollars in millions) |
|
|
2023 |
|
|
Revenues |
|
|
2022 |
|
|
Revenues |
||
|
|
|
|
|
|
|
|
|
||||||
Revenues |
|
|
|
|
|
|
|
|
||||||
Life Sciences Solutions |
|
$ |
9,977 |
|
|
23.3 |
% |
|
$ |
13,532 |
|
|
30.1 |
% |
Analytical Instruments |
|
|
7,263 |
|
|
16.9 |
% |
|
|
6,624 |
|
|
14.7 |
% |
Specialty Diagnostics |
|
|
4,405 |
|
|
10.3 |
% |
|
|
4,763 |
|
|
10.6 |
% |
Laboratory Products and Biopharma Services |
|
|
23,041 |
|
|
53.8 |
% |
|
|
22,511 |
|
|
50.1 |
% |
Eliminations |
|
|
(1,829 |
) |
|
-4.3 |
% |
|
|
(2,515 |
) |
|
-5.5 |
% |
Consolidated revenues |
|
$ |
42,857 |
|
|
100.0 |
% |
|
$ |
44,915 |
|
|
100.0 |
% |
|
|
|
|
|
|
|
|
|
||||||
Segment income and segment income margin |
|
|
|
|
|
|
|
|
||||||
Life Sciences Solutions |
|
$ |
3,420 |
|
|
34.3 |
% |
|
$ |
5,582 |
|
|
41.2 |
% |
Analytical Instruments |
|
|
1,908 |
|
|
26.3 |
% |
|
|
1,507 |
|
|
22.8 |
% |
Specialty Diagnostics |
|
|
1,124 |
|
|
25.5 |
% |
|
|
1,024 |
|
|
21.5 |
% |
Laboratory Products and Biopharma Services |
|
|
3,358 |
|
|
14.6 |
% |
|
|
2,872 |
|
|
12.8 |
% |
Subtotal reportable segments |
|
|
9,810 |
|
|
22.9 |
% |
|
|
10,985 |
|
|
24.5 |
% |
Cost of revenues adjustments (a) |
|
|
(95 |
) |
|
-0.2 |
% |
|
|
(46 |
) |
|
-0.1 |
% |
Selling, general and administrative expenses adjustments (b) |
|
|
(59 |
) |
|
-0.1 |
% |
|
|
(37 |
) |
|
-0.1 |
% |
Restructuring and other costs (c) |
|
|
(459 |
) |
|
-1.1 |
% |
|
|
(114 |
) |
|
-0.3 |
% |
Amortization of acquisition-related intangible assets |
|
|
(2,338 |
) |
|
-5.5 |
% |
|
|
(2,395 |
) |
|
-5.3 |
% |
Consolidated GAAP operating income |
|
$ |
6,859 |
|
|
16.0 |
% |
|
$ |
8,393 |
|
|
18.7 |
% |
(a) Adjusted results in 2023 and in 2022 exclude charges for the sale of inventories revalued at the date of acquisition and charges for inventory write-downs associated with large-scale abandonment of product lines. Adjusted results in 2023 also exclude |
(b) Adjusted results in 2023 and 2022 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges associated with product liability litigation. |
(c) Adjusted results in 2023 and 2022 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, charges for environmental-related matters, abandoned facility and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude |
(d) Adjusted results in 2023 and 2022 exclude net gains/losses on investments. Adjusted results in 2022 also exclude |
(e) Adjusted results in 2023 and 2022 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements (including a |
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests. |
|
Note: |
Consolidated depreciation expense is |
Organic and Core organic revenue growth |
|
Year ended |
|
|
December 31, 2023 |
Revenue growth |
|
- |
Acquisitions |
|
|
Currency translation |
|
|
Organic revenue growth (non-GAAP measure) * |
|
- |
COVID-19 testing revenue |
|
- |
Core organic revenue growth (non-GAAP measure) * |
|
|
* Results may not sum due to rounding. |
|
|
Note: |
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
Condensed Consolidated Balance Sheets (unaudited) |
|
|
|
|
||
|
|
|
|
|
||
|
|
December 31, |
|
December 31, |
||
(In millions) |
|
2023 |
|
2022 |
||
|
|
|
|
|
||
Assets |
|
|
|
|
||
Current assets: |
|
|
|
|
||
Cash and cash equivalents |
|
$ |
8,077 |
|
$ |
8,524 |
Accounts receivable, net |
|
|
8,221 |
|
|
8,115 |
Inventories |
|
|
5,088 |
|
|
5,634 |
Other current assets |
|
|
3,203 |
|
|
2,956 |
Total current assets |
|
|
24,589 |
|
|
25,229 |
Property, plant and equipment, net |
|
|
9,448 |
|
|
9,280 |
Acquisition-related intangible assets, net |
|
|
16,670 |
|
|
17,442 |
Other assets |
|
|
3,999 |
|
|
4,007 |
Goodwill |
|
|
44,020 |
|
|
41,196 |
Total assets |
|
$ |
98,726 |
|
$ |
97,154 |
|
|
|
|
|
||
Liabilities, redeemable noncontrolling interest and equity |
|
|
|
|
||
Current liabilities: |
|
|
|
|
||
Short-term obligations and current maturities of long-term obligations |
|
$ |
3,609 |
|
$ |
5,579 |
Other current liabilities |
|
|
10,403 |
|
|
11,431 |
Total current liabilities |
|
|
14,012 |
|
|
17,010 |
Other long-term liabilities |
|
|
6,564 |
|
|
7,087 |
Long-term obligations |
|
|
31,308 |
|
|
28,909 |
Redeemable noncontrolling interest |
|
|
118 |
|
|
116 |
Total equity |
|
|
46,724 |
|
|
44,032 |
Total liabilities, redeemable noncontrolling interest and equity |
|
$ |
98,726 |
|
$ |
97,154 |
Condensed Consolidated Statements of Cash Flows (unaudited) |
|
|
|
|
||||
|
|
|
|
|
||||
|
|
Year ended |
||||||
|
|
December 31, |
|
December 31, |
||||
(In millions) |
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
||||
Operating activities |
|
|
|
|
||||
Net income |
|
$ |
5,955 |
|
|
$ |
6,960 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
|
3,406 |
|
|
|
3,381 |
|
Change in deferred income taxes |
|
|
(1,300 |
) |
|
|
(995 |
) |
Other non-cash expenses, net |
|
|
882 |
|
|
|
857 |
|
Changes in assets and liabilities, excluding the effects of acquisitions |
|
|
(537 |
) |
|
|
(1,049 |
) |
Net cash provided by operating activities |
|
|
8,406 |
|
|
|
9,154 |
|
|
|
|
|
|
||||
Investing activities |
|
|
|
|
||||
Acquisitions, net of cash acquired |
|
|
(3,660 |
) |
|
|
(39 |
) |
Purchases of property, plant and equipment |
|
|
(1,479 |
) |
|
|
(2,243 |
) |
Proceeds from sale of property, plant and equipment |
|
|
87 |
|
|
|
24 |
|
Proceeds from cross-currency interest rate swap interest settlements |
|
|
70 |
|
|
|
15 |
|
Other investing activities, net |
|
|
(160 |
) |
|
|
84 |
|
Net cash used in investing activities |
|
|
(5,142 |
) |
|
|
(2,159 |
) |
|
|
|
|
|
||||
Financing activities |
|
|
|
|
||||
Net proceeds from issuance of debt |
|
|
5,942 |
|
|
|
3,193 |
|
Repayment of debt |
|
|
(5,782 |
) |
|
|
(375 |
) |
Net proceeds from issuance of commercial paper |
|
|
1,620 |
|
|
|
1,526 |
|
Repayment of commercial paper |
|
|
(1,935 |
) |
|
|
(3,690 |
) |
Purchases of company common stock |
|
|
(3,000 |
) |
|
|
(3,000 |
) |
Dividends paid |
|
|
(523 |
) |
|
|
(455 |
) |
Other financing activities, net |
|
|
56 |
|
|
|
(9 |
) |
Net cash used in financing activities |
|
|
(3,622 |
) |
|
|
(2,810 |
) |
|
|
|
|
|
||||
Exchange rate effect on cash |
|
|
(82 |
) |
|
|
(139 |
) |
(Decrease) increase in cash, cash equivalents and restricted cash |
|
|
(440 |
) |
|
|
4,046 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
8,537 |
|
|
|
4,491 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
8,097 |
|
|
$ |
8,537 |
|
|
|
|
|
|
||||
Free cash flow (non-GAAP measure) |
|
$ |
7,014 |
|
|
$ |
6,935 |
|
Note: |
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
Supplemental Information Regarding Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of acquisitions/divestitures and the effects of currency translation. We also report Core organic revenue growth, which is reported revenue growth, excluding the impacts of COVID-19 testing revenue, and excluding the impacts of acquisitions/divestitures and the effects of currency translation. We report these measures because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures, foreign currency translation and/or COVID-19 testing on revenues. Thermo Fisher management uses these measures to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.
We report adjusted operating income, adjusted operating income margin, adjusted net income, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:
- Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-related costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
- Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities are not indicative of our normal operating costs.
- Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
- The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
- The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.
We report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.
Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher Scientific’s results computed in accordance with GAAP.
The non-GAAP financial measures of Thermo Fisher Scientific’s results of operations and cash flows included in this press release are not meant to be considered superior to or a substitute for Thermo Fisher Scientific’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the tables above.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130329002/en/
Media Contact Information:
Sandy Pound
Thermo Fisher Scientific
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information:
Rafael Tejada
Thermo Fisher Scientific
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
Source: Thermo Fisher Scientific Inc.
FAQ
What was Thermo Fisher Scientific Inc.'s Q4 revenue for 2023?
What was Thermo Fisher Scientific Inc.'s full-year revenue for 2023?
What was Thermo Fisher Scientific Inc.'s Q4 GAAP diluted EPS for 2023?
What was Thermo Fisher Scientific Inc.'s Q4 adjusted EPS for 2023?
What acquisitions did Thermo Fisher Scientific Inc. complete in 2023?
What is Thermo Fisher Scientific Inc.'s revenue guidance for 2024?
